- Home
- TLPH vs KZIA Comparison
TLPH vs KZIA Comparison
Compare TLPH & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | KZIA |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.3M | 154.5M |
| IPO Year | 2010 | 2002 |
Fundamental Metrics
Financial Performance| Metric | TLPH | KZIA |
|---|---|---|
| Price | $1.20 | $13.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | ★ 311.9K | 189.1K |
| Earning Date | 05-13-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,151,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $4.86 |
| 52 Week High | $1.57 | $17.40 |
Technical Indicators
Market Signals| Indicator | TLPH | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 42.49 | 50.88 |
| Support Level | $0.74 | $11.39 |
| Resistance Level | $1.48 | $14.75 |
| Average True Range (ATR) | 0.08 | 0.98 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 20.51 | 53.98 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.